BioStem Technologies, Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care. Since our founding in 2014, we’ve pursued a singular goal: changing lives for the better with the power of superior processes and an unwavering commitment to innovation.

Leveraging our proprietary BioREtain® processing method, we manufacture perinatal tissue allografts at the highest levels of quality. BioREtain has been developed by applying the latest research in regenerative medicine, focused on maintaining natural growth factors and preserving tissue structure. Our allografts, including VENDAJE®, VENDAJE AC®, VENDAJE OPTIC® and AmnioWrap2TM are trusted by top clinicians across a range of specialties.

  • A man in a dark suit points at research posters displayed on a white board at a conference. The posters contain scientific text, images, and case reports related to wound healing treatments.

    Article

    The primary objective of this randomized controlled trial was to determine whether non-ischemic, non-infected Wagner Grade 1-2 diabetic foot ulcers (DFUs) treated with standard care plus BioRetain Amniochorion (BR-AC) resulted in a higher probability of complete wound closure compared to standard care alone.

    View Full Size
  • A man in a dark suit points at research posters displayed on a white board at a conference. The posters contain scientific text, images, and case reports related to wound healing treatments.

Podium Presenation

Secure Your Spot at TRES Spring in 2026

Register Your Interest

Be the First to Register for TRES Spring 2026

Join clinical leaders and industry innovators at the next evolution in evidence-based wound care.

📅 February 27–28, 2026

🌐 Dedicated website goes live October 2026.